Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pengfei Cui
Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer
Journal of Cancer
Oncology
Related publications
P013 Anti-Pd-1 Combination Therapy as Second Line Treatment or Beyond in Patients With Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Korean Journal of Internal Medicine
Internal Medicine
The Efficacy and Safety of Anti-Pd-1/Pd-L1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First-Line Treatment for Advanced Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
Erratum: The Efficacy and Safety of Anti‐PD‐1/Pd‐l1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First‐line Treatment for Advanced Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
Radiotherapy With or Without Concomitant Chemotherapy as Pre- Or Postoperative Therapy in Non-Small Cell Lung Cancer
Journal of Cancer Science & Therapy
Second-Line Therapy for Elderly Patients With Non-Small Cell Lung Cancer Who Failed Previous Chemotherapy Is as Effective as for Younger Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Treatment Results Including More Than Third-Line Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer
Oncology Letters
Cancer Research
Oncology
